Equities Analysts Offer Predictions for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, November 4th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($1.22) per share for the year, up from their prior estimate of ($2.54). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

A number of other equities analysts also recently issued reports on the company. HC Wainwright increased their price target on Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Tuesday. B. Riley began coverage on Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price objective on the stock. Morgan Stanley raised their price objective on Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a research report on Tuesday. Guggenheim raised their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $154.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $180.75.

Axsome Therapeutics Price Performance

AXSM opened at $135.69 on Thursday. Axsome Therapeutics has a 12-month low of $75.56 and a 12-month high of $139.13. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The business’s fifty day simple moving average is $124.02 and its 200-day simple moving average is $113.19. The company has a market capitalization of $6.77 billion, a price-to-earnings ratio of -26.76 and a beta of 0.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The firm had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics’s revenue for the quarter was up 63.2% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Moors & Cabot Inc. raised its stake in shares of Axsome Therapeutics by 4.5% in the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after purchasing an additional 100 shares during the last quarter. Meridian Wealth Management LLC raised its stake in shares of Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock worth $2,687,000 after purchasing an additional 103 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after purchasing an additional 107 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Axsome Therapeutics by 6.8% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 2,101 shares of the company’s stock worth $255,000 after purchasing an additional 134 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in shares of Axsome Therapeutics by 0.3% in the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock worth $4,621,000 after purchasing an additional 136 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 21,775 shares of the stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $972,228.21. This trade represents a 75.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $115.96, for a total value of $1,159,600.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 407,271 shares of company stock valued at $50,640,415. 22.30% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.